Serum micronutrients and prealbumin during development and recovery of chemotherapy-induced peripheral neuropathy.
Chemotherapy-induced peripheral neuropathy (CIPN) is a frequent adverse event. Nutritional status can become impaired in cancer patients, potentially contributing to neuropathy's evolution. Our aim was to evaluate serum micronutrients and prealbumin in a cohort of 113 solid-cancer patients receiving platinum and taxane compounds during the development and recovery of neuropathy, up to 1 year after finishing treatment. CIPN was graded according to Total Neuropathy Score(©) and NCI.CTCv3 at T0 (baseline), T1 (1-3 months), and T12 (12 months) after chemotherapy. CIPN was classified as asymptomatic (< grade 2) or symptomatic (≥2). CIPN recovery was defined as ≥1 grade improvement at T12. Symptomatic CIPN developed in 52% of patients. Symptomatic patients presented a higher increase in TNSc (p < 0.001), in TNSr(©) (p < 0.001), and decrease in sural (p < 0.001) and radial nerve conduction (p < 0.001). No significant differences with any of the micronutrients were observed along T0-T1 period between severity or chemotherapy groups. By T12, symptomatic patients without recovery had a decrease in vitamin E levels (p = 0.019) and prealbumin (p = 0.062) compared with those symptomatic that improved. A correlation between the variation of vitamin E and prealbumin at T0-T1 (r = 0.626, p = 0.001) and T1-T12 (r = 0.411, p = 0.06) was observed. After chemotherapy treatment, the improvement of patients displaying symptomatic neuropathy is related to vitamin E and prealbumin serum levels. Our results suggest that nutritional status can play a role in CIPN recovery.
Neuro-Oncology Unit, Hospital Universitari de Bellvitge - Institut Català d'Oncologia - IDIBELL, Barcelona, Spain.|Institute of Neurosciences, Department of Cell Biology, Physiology and Immunology, Universitat Autònoma de Barcelona, and Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Bellaterra, Spain.
Roser
R
Velasco
Medical Oncology Department, Institut Català d'Oncologia, Barcelona, Spain.
Cristina
C
Santos
Medical Oncology Department, Institut Català d'Oncologia, Barcelona, Spain.
Gemma
G
Soler
Neuro-Oncology Unit, Hospital Universitari de Bellvitge - Institut Català d'Oncologia - IDIBELL, Barcelona, Spain.|Medical Oncology Department, Institut Català d'Oncologia, Barcelona, Spain.
Miguel
M
Gil-Gil
Medical Oncology Department, Institut Català d'Oncologia, Barcelona, Spain.
Sonia
S
Pernas
Medical Oncology Department, Institut Català d'Oncologia, Barcelona, Spain.
Maica
M
Galan
Medical Oncology Department, Institut Català d'Oncologia, Barcelona, Spain.
Ramon
R
Palmero
Neuro-Oncology Unit, Hospital Universitari de Bellvitge - Institut Català d'Oncologia - IDIBELL, Barcelona, Spain.|Institute of Neurosciences, Department of Cell Biology, Physiology and Immunology, Universitat Autònoma de Barcelona, and Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Bellaterra, Spain.
Jordi
J
Bruna
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D018977:Micronutrients / Q000097:blood*; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced*; D011228:Prealbumin / Q000378:metabolism*; D012189:Retrospective Studies
D000970:Antineoplastic Agents; D018977:Micronutrients; D011228:Prealbumin
chemotherapy-induced peripheral neuropathy; nutritional status; platinum; serum micronutrients; taxane